Tags : RAF

Jazz Pharmaceuticals Acquires Redx Pharma’s Pre-clinical Pan-RAF Inhibitor Program for

Tuba Khan July 10, 2019

Shots: Redx to receive $3.5M up front, up to $203M as milestone & royalties on sales and will be responsible for pre-clinical activities of the program under a separate collaboration […]readmore

Tags : RAF

Jazz Pharmaceuticals Acquires Redx Pharma’s Pre-clinical Pan-RAF Inhibitor Program for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : RAF

﻿Jazz Pharmaceuticals Acquires Redx Pharma’s Pre-clinical Pan-RAF Inhibitor Program for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Jazz Pharmaceuticals Acquires Redx Pharma’s Pre-clinical Pan-RAF Inhibitor Program for